Navigation Links
AtriCure Reports First Quarter 2008 Financial Results
Date:5/6/2008

atrial fibrillation, or AF, a rapid, irregular quivering of the upper chambers of the heart. Additionally, medical journals and leading cardiothoracic surgeons have described the AtriCure Isolator(R) system as a promising treatment alternative for patients who may be candidates for sole-therapy minimally invasive procedures. AF affects more than 5.5 million people worldwide and predisposes them to a five-fold increased risk of stroke.

The FDA has cleared the AtriCure Isolator(R) system, including its Isolator Synergy(TM) ablation clamps, and AtriCure's multifunctional pen and Coolrail(TM) linear ablation device, for the ablation, or destruction, of cardiac tissue during surgical procedures. Additionally, the FDA has cleared AtriCure's multifunctional pen for temporary pacing, sensing, stimulating and recording during the evaluation of cardiac arrhythmias. To date, the FDA has not cleared or approved AtriCure's products for the treatment of AF. AtriCure's left atrial appendage clip system has not been approved for commercial use. It is currently being used in clinical evaluations in Europe.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward- looking statements include statements that address activities, events or developments that AtriCure expects, believes or anticipates will or may occur in the future, such as earnings estimates, other predictions of financial performance, launches by AtriCure of new products and market acceptance of AtriCure's products. Forward-looking statements are based on AtriCure's experience and perception of current conditions, trends, expected future developments and other factors it believes are appropriate under the circumstances and are subject to numerous risks and uncertainties, many of which are beyond AtriCure's control. These risks and uncertainties include the rate and degree of market acceptanc
'/>"/>

SOURCE AtriCure, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. AtriCure Announces Initiation of the ABLATE Pivotal Trial to Evaluate the Isolator Synergy(TM) Bipolar Ablation System to Treat Atrial Fibrillation
2. Genetic Engineering and Biotechnology News (GEN) Reports on Early ADMET Use
3. Vion Reports 2008 First Quarter Results
4. eResearchTechnology Reports First Quarter 2008 Results
5. MannKind Corporation Reports First Quarter Financial Results
6. Verenium Reports Financial Results for the First Quarter 2008
7. ev3 Inc. Reports 2008 First Quarter Financial Results and Revised 2008 Guidance
8. United Therapeutics Reports First Quarter 2008 Financial Results
9. Endocare Reports 2008 First Quarter Financial Results
10. AMICAS Reports Financial Results for the First Quarter Ended March 31, 2008
11. LeMaitre Vascular Reports Q1 2008 Revenue of $11.8 Million, a 20% Increase
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... in the Nation ,, PHILADELPHIA, Dec. 16 ... has been granted Magnet(R) recognition by the American ... is one of the highest levels of recognition ... places Hahnemann among the five percent of hospitals ... distinction. ,, At 9:00 am on Monday, Hahnemann ...
(Date:12/16/2009)... biotechnology company,s revenues increase 22% for fiscal 2009; ... 2010 , TORONTO, Dec. 16 /PRNewswire-FirstCall/ - Microbix ... virology and biological technologies, today reported financial results ... fiscal year ended September 30, 2009, Microbix reported ... the same period in 2008. For fourth-quarter 2009, ...
(Date:12/16/2009)... HSP A has been found to be effectinve in improving yelds ... ... -- Nu-Tek BioSciences, LLC. ( www.nu-tekproducts.com ) is meeting the demand ... manufactured by Nutricepts, Inc. (Burnsville, Mn), is a high quality Soy ... HSP-A has been found to be especially effective in improving ...
(Date:12/15/2009)... China, Dec. 15 /PRNewswire-Asia-FirstCall/ -- China Sky One,Medical, ... (Nasdaq: CSKI ), a,leading fully integrated pharmaceutical ... Republic of China ("PRC"), today,announced that the Company ... the 2009,Edition of the National Basic Medical Insurance, ... The 30 medicines treat ...
Breaking Biology Technology:Hahnemann University Hospital Granted Magnet(R) Status 2Hahnemann University Hospital Granted Magnet(R) Status 3Microbix' Pipeline Set To Reach Milestones In 2010 2Microbix' Pipeline Set To Reach Milestones In 2010 3Microbix' Pipeline Set To Reach Milestones In 2010 4Microbix' Pipeline Set To Reach Milestones In 2010 5Microbix' Pipeline Set To Reach Milestones In 2010 6Microbix' Pipeline Set To Reach Milestones In 2010 7Microbix' Pipeline Set To Reach Milestones In 2010 8China Sky Medical, Inc. Has 30 Medicines that will Be Included in China's National Insurance Directory 2China Sky Medical, Inc. Has 30 Medicines that will Be Included in China's National Insurance Directory 3
... 5 /PRNewswire-FirstCall/ - YM BioSciences Inc.,(AMEX: YMI ... that identifies,develops and commercializes differentiated products for patients ... David Allan, Chairman and CEO, at,12:00pm EDT today, ... are invited to discuss the preliminary results obtained ...
... -- Record consolidated revenues of $14.9 million -- ... of $2.3 million - 49% growth ... million credit facility - expands capital resources, -- Reported MIS procedure times of 60 minutes and ... days ...
... MONTREAL, Aug. 5 /PRNewswire-FirstCall/ - ProMetic Life ... has reached an understanding,with a fully integrated, ... and global commercialization of several biopharmaceutical,products in ... to licensing, development and milestone fees as ...
Other Biology Technology:NOTICE OF YM BIOSCIENCES CONFERENCE CALL TO DISCUSS PHASE II DATA FOR NIMOTUZUMAB IN METASTATIC COLORECTAL CANCER 2AtriCure Reports Record Second Quarter 2008 Financial Results 2AtriCure Reports Record Second Quarter 2008 Financial Results 3AtriCure Reports Record Second Quarter 2008 Financial Results 4AtriCure Reports Record Second Quarter 2008 Financial Results 5AtriCure Reports Record Second Quarter 2008 Financial Results 6AtriCure Reports Record Second Quarter 2008 Financial Results 7AtriCure Reports Record Second Quarter 2008 Financial Results 8Prometic reaches understanding for commercialisation of several biopharmaceutical products and strategic investment 2Prometic reaches understanding for commercialisation of several biopharmaceutical products and strategic investment 3
(Date:12/16/2009)... A University of Maryland School of Medicine researcher will ... nation,s most prominent scientists in the field of stem ... and Preventive Medicine, was chosen by the National Heart, ... of this consortium of national experts, which will be ... center will be funded by a $30 million grant ...
(Date:12/16/2009)... BIO-key International, Inc. (OTC Bulletin ... safety and finger-based biometric identification solutions, announced ... a Special Shareholder Meeting held today approved ... Division to Interact911 Mobile Systems Inc. Of ... favor and 1.2% were opposed. ,, (Logo: ...
(Date:12/16/2009)... European Union (EU) member states are spending ... increasingly subjected to unauthorised immigration and illegal ... security and IT-based systems will boost the ... ) ,, New analysis from Frost & ... Market Assessment - European Union , finds ...
Breaking Biology News(10 mins):University of Maryland School of Medicine receives $30 million to coordinate stem cell consortium 2University of Maryland School of Medicine receives $30 million to coordinate stem cell consortium 3BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 2BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 3Increased Spending on the EU's External Borders to Drive the Border Security Market, Says Frost & Sullivan 2Increased Spending on the EU's External Borders to Drive the Border Security Market, Says Frost & Sullivan 3Innovative Medical Technology Companies From Around the World Selected to Present Profiles to Industry Leaders 26 Financiers at AdvaMed 2009 57994 1Innovative Medical Technology Companies From Around the World Selected to Present Profiles to Industry Leaders 26 Financiers at AdvaMed 2009 57994 2Innovative Medical Technology Companies From Around the World Selected to Present Profiles to Industry Leaders 26 Financiers at AdvaMed 2009 57994 3Innovative Medical Technology Companies From Around the World Selected to Present Profiles to Industry Leaders 26 Financiers at AdvaMed 2009 57994 4Innovative Medical Technology Companies From Around the World Selected to Present Profiles to Industry Leaders 26 Financiers at AdvaMed 2009 57994 5Healthcare Reform Must Include Full Participation by Licensed Professional Insurance Agents 57991 1Healthcare Reform Must Include Full Participation by Licensed Professional Insurance Agents 57991 2Democratic Governors Urge Congress to Act on Health Insurance Reform 57988 1Democratic Governors Urge Congress to Act on Health Insurance Reform 57988 2
... That Cause Cavities and Gum Disease , Blue ... hydrogen peroxide (H 2 O 2 ) combined may be ... biofilms that can cause cavities and gingivitis. The researchers ... California San Francisco report their findings in the July 2008 ...
... continental shelf and drive carbon capture in the deep ocean, ... finding does not change estimates of the oceans, total carbon ... oceans and major rivers. , The tropical North Atlantic had ... of ocean life. A 2007 study estimated that ocean,s contribution ...
... a second strain of the virus, the two viral ... strain of the virus. It is known that ... leads to a loss of immune control of viral ... Research Center at Massachusetts General Hospital (PARC/MGH) shows that ...
Other Biology News:Tips from the Journals of the American Society for Microbiology 2Tips from the Journals of the American Society for Microbiology 3Amazon powers tropical ocean's carbon sink 2Viral recombination another way HIV fools the immune system 2
... StabilGuard Biomolecule Stabilizer is a bovine protein-free ... is an aqueous solution that contains non-toxic ... saline), pH 6.6 - 7.2, and does ... maintains the activity of antibodies and other ...
... The lyophilization stabilizer is designed ... process and for long-term storage. ... toxic ingredients. It is a ... pH 7.2, and is superior to ...
... The CERTOMAT IS, a true benchtop incubator-shaker, ... shakers. Having a footprint of 540 x ... a large incubation chamber (370 x 505 x ... orbits, the CERTOMAT IS is ideal for shaking ...
... smallest thermal cyclers on the market, which is ... (20 samples) or 0.2ml microtube (25 samples) block ... cooling rate of 3.6C/sec and 2.0C/sec respectively ... track programming with new quick dial facility ...
Biology Products: